Renato Patrone1, Vincenza Granata2,3, Andrea Belli4, Raffaele Palaia4, Vittorio Albino4, Mauro Piccirillo4, Roberta Fusco5, Fabiana Tatangelo6, Guglielmo Nasti7, Antonio Avallone7, Francesco Izzo4. 1. PhD ICTH, University Federico II, Via Sergio Pansinin 5, 80131, Naples, Italy. 2. Department of Support to Cancer Pathways Diagnostics Area, Radiology Unit, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy. v.granata@istitutotumori.na.it. 3. Radiology Division, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy. v.granata@istitutotumori.na.it. 4. Department Corp-S Care and Research of Cancer of the Abdominal District, Hepatobiliary Unit, "Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - Napoli", Naples, Italy. 5. Department of Support to Cancer Pathways Diagnostics Area, Radiology Unit, "Istituto Nazionale Tumori IRCCS Fondazione Pascale - IRCCS di Napoli", Naples, Italy. 6. Department of Support to Cancer Pathways Diagnostics Area, Pathology and Cytopathology Unit, "Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - IRCCS Napoli", Naples, Italy. 7. Department Corp-S Care and Research of Cancer of the Abdominal District, Oncology Unit, "Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - IRCCS Napoli", Naples, Italy.
Abstract
BACKGROUND: Biloma, an encapsulated collection of bile outside the biliary tree, supported by a predominantly iatrogenic biliary fistula, and bile likeage are two of the most important surgical complications after liver resection. We, hypothesized to conduct a project aimed to prevent, or reduce, the formation of biloma or biliary fistula applying on the hepatic resection area the cyanoacrylate glue (Glubran2). METHODS: We searched in our surgical database all patients underwent liver resection for mCRC from January 2013 to December 2018 and we found a total of 510 patients. 205 patients for Group A (study population: included patients in which we have used Glubran2 during surgical procedure) and 113 patients for Group B (control group), were enrolled. RESULTS: In both Groups no patients died during hospitalization and the 30-day mortality was 0 %. During follow-up in Group A, a biliary fistula was found in 2 patients (1 %) versus 3 patients in the Group B (2,6 %). In patients enrolled in Group A no adverse event were reported relate to the use of Glubran2. CONCLUSIONS: It is possible to affirm that the use of Glubran2 as biliostatic agent after liver resection is useful to prevent bile leakage complication and biloma formation and its use demonstrated to be safe and feasible during liver surgery.
BACKGROUND: Biloma, an encapsulated collection of bile outside the biliary tree, supported by a predominantly iatrogenic biliary fistula, and bile likeage are two of the most important surgical complications after liver resection. We, hypothesized to conduct a project aimed to prevent, or reduce, the formation of biloma or biliary fistula applying on the hepatic resection area the cyanoacrylate glue (Glubran2). METHODS: We searched in our surgical database all patients underwent liver resection for mCRC from January 2013 to December 2018 and we found a total of 510 patients. 205 patients for Group A (study population: included patients in which we have used Glubran2 during surgical procedure) and 113 patients for Group B (control group), were enrolled. RESULTS: In both Groups no patientsdied during hospitalization and the 30-day mortality was 0 %. During follow-up in Group A, a biliary fistula was found in 2 patients (1 %) versus 3 patients in the Group B (2,6 %). In patients enrolled in Group A no adverse event were reported relate to the use of Glubran2. CONCLUSIONS: It is possible to affirm that the use of Glubran2 as biliostatic agent after liver resection is useful to prevent bile leakage complication and biloma formation and its use demonstrated to be safe and feasible during liver surgery.
Entities:
Keywords:
Bile duct injury; Chemotherapy; Efficacy; Hepatic resection; Liver metastases
Authors: Andrea Frilling; Gregor A Stavrou; Hans-Jörg Mischinger; Bernard de Hemptinne; Mogens Rokkjaer; Jürgen Klempnauer; Anders Thörne; Beat Gloor; Susanne Beckebaum; Mohamed F A Ghaffar; Christoph E Broelsch Journal: Langenbecks Arch Surg Date: 2005-02-19 Impact factor: 3.445
Authors: Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo Journal: Infect Agent Cancer Date: 2021-07-19 Impact factor: 2.965